In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes. While this is a good finding, upcoming trials of other medications in this class will help put this drug into a context.
1) EMPA-REG OUTCOME
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type-2 Diabetes
NEJM 2015 DOI: 10.1056/NEJMoa1504720